Cover Image

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans

Saved in:

Bibliographic Details
Main Authors:	Cara Barber, MD, MPH (Author), Eingun James Song, MD (Author)
Format:	Book
Published:	Elsevier, 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dermoscopy of telangiectasia macularis eruptiva perstans
by: Smriti Kumar, et al.
Published: (2020)

Telangiectasia macularis eruptiva perstans in the presence of liver cirrhosis
by: Alisen Huang, MS, et al.
Published: (2020)

Dermatoscopic findings in telangiectasia macularis eruptiva perstans
by: Natasha Unterstell, et al.
Published: (2013)

Telangiectasia Macularis Eruptiva Perstans: more than skin deep
by: Casey E. Watkins, et al.
Published: (2011)

Telangiectasia macularis eruptiva perstans: a report of two cases
by: Qiufeng HUANG, et al.
Published: (2023)

Um Novo Olhar sobre a Telangiectasia Macularis Eruptiva Perstans
by: André Pinho, et al.
Published: (2016)

Newly Developed Psoriasis in a Patient with Telangiectasia Macularis Eruptiva Perstans and Systemic Mastocytosis Treated with Interferon
by: Tatiana Péčová, et al.
Published: (2021)

Persistent Facial Flushing in a Patient with Telangiectasia Macularis Eruptiva Perstans: An Unusual but Should Emphasized Clinical Finding
by: He X, et al.
Published: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
by: Cara Barber, MD, MPH, et al.
Published: (2022)

Telangiectasia macularis eruptive perstans in an HIV-positive patient: true association or mere coincidence?
by: Rajesh Kumar Mandal, et al.
Published: (2016)

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma
by: George D. Glinos, MD, et al.
Published: (2021)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024)

Telangiectasia Macularis Multiplex Acquisita and its Potential Association with Calcium Channel Blockers: A Retrospective Study of 46 Chinese Patients
by: Tian Chen, et al.
Published: (2024)

Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series
by: Kanako Tsunoda, MD, PhD, et al.
Published: (2024)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
by: Angelo Ruggiero, et al.
Published: (2022)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
by: Reddy V, et al.
Published: (2020)

Successful treatment of 2 imported cases of Mansonella perstans infection.
by: Hilmir Asgeirsson, et al.
Published: (2017)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
by: Marta Kołt-Kamińska, et al.
Published: (2023)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018)

Successful treatment of facial telangiectasia from carcinoid syndrome with pulsed dye laser therapy
by: Roy Jiang, MD, PhD, et al.
Published: (2023)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
by: Fabrizio Calapai, et al.
Published: (2023)

Acquired perforating dermatosis associated with risankizumab
by: Munira Alhadlg, MD, et al.
Published: (2024)

PIGMENTAÇÃO MACULAR ERUPTIVA IDIOPÁTICA NA CRIANÇA
by: Paula Maio, et al.
Published: (2013)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
by: Al Muqrin AM, et al.
Published: (2022)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021)

Risankizumab-associated lichen planus pemphigoides
by: Jessica Sparks, et al.
Published: (2023)

Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVE
by: Nicoletta Bernardini, et al.
Published: (2024)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
by: Gracia-Cazaña T, et al.
Published: (2023)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
by: Giacomo Caldarola, et al.
Published: (2023)

Erythema Dyschromicum Perstans
by: Umap Pradeep S
Published: (1996)

Erythema dyschromicum perstans following neurotoxin injection for facial rhytides
by: Corley C. Pruneda, MD, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023)